Cell therapy is the introduction of selected, and sometimes engineered, cells into a patient, harnessing the power of a patient’s immune system to combat their disease. The therapy may have wide applications as a cancer treatment, with the potential for cure in some patients.

Syncona has a world-leading cell therapy franchise developing products with the potential to treat patients across a range of diseases.

The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across innovative areas of cell therapy including: CAR-T, Tumour Infiltrating Lymphocytes, TCRs, T-Regulatory cells and macrophages.

Key facts*

£253m

value of cell therapy portfolio

4

number of clinical programmes

5

financing rounds in the year

Our Cell Therapy portfolio companies

Our domain areas

Syncona has deep domain expertise across four key therapeutic areas.

*Unless stated all data at 31 December 2020